8月20日盘后,恒瑞医药(SH600276,股价49.50元,市值3285亿元)连发四份公告,宣布其自主研发的1类新药富马酸立康可泮(HRS-5965)胶囊获国家药监局批准上市,同时旗下三款创新药SHR-8203注射液、SHR-7012注射液、HRS-3095片分别获得药物临床试验批准通知书,研发管线再迎密集进展。 两款创新药获临床试验批准布局红斑狼疮与晚期实体瘤 根据公告,恒瑞医药子公司...
Source Link8月20日盘后,恒瑞医药(SH600276,股价49.50元,市值3285亿元)连发四份公告,宣布其自主研发的1类新药富马酸立康可泮(HRS-5965)胶囊获国家药监局批准上市,同时旗下三款创新药SHR-8203注射液、SHR-7012注射液、HRS-3095片分别获得药物临床试验批准通知书,研发管线再迎密集进展。 两款创新药获临床试验批准布局红斑狼疮与晚期实体瘤 根据公告,恒瑞医药子公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.